Validation of disease-specific biomarkers for the early detection of bronchopulmonary dysplasia

To demonstrate and validate the improvement of current risk stratification for bronchopulmonary dysplasia (BPD) early after birth by plasma protein markers (sialic acid-binding Ig-like lectin 14 (SIGLEC-14), basal cell adhesion molecule (BCAM), angiopoietin-like 3 protein (ANGPTL-3)) in extremely pr...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric research 2023-02, Vol.93 (3), p.625-632
Main Authors: Kindt, Alida S D, Förster, Kai M, Cochius-den Otter, Suzan C M, Flemmer, Andreas W, Hauck, Stefanie M, Flatley, Andrew, Kamphuis, Juliette, Karrasch, Stefan, Behr, Jürgen, Franz, Axel, Härtel, Christoph, Krumsiek, Jan, Tibboel, Dick, Hilgendorff, Anne
Format: Article
Language:English
Subjects:
Biomarkers
Bronchopulmonary Dysplasia - prevention & control
Clinical
Decision making
Gestational Age
Humans
Infant
Infant, Extremely Premature
Infant, Newborn
Lung diseases
Newborn babies
Premature babies
Proteome
Proteomics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To demonstrate and validate the improvement of current risk stratification for bronchopulmonary dysplasia (BPD) early after birth by plasma protein markers (sialic acid-binding Ig-like lectin 14 (SIGLEC-14), basal cell adhesion molecule (BCAM), angiopoietin-like 3 protein (ANGPTL-3)) in extremely premature infants. Proteome screening in first-week-of-life plasma samples of n = 52 preterm infants
ISSN:0031-3998
1530-0447
DOI:10.1038/s41390-022-02093-w